| PET imaging in the management of tumors of testis and ovary: current thinking and future directions. | |
| | |
MedLine Citation:
|
PMID: 18846028 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The role of fluoro-D-deoxyglucose positron-emission tomography (FDG-PET) in testicular malignancies has been examined in various studies primarily in three specific settings: 1) differentiation of active disease from fibrosis/mature teratoma in patients with residual mass following chemotherapy and evaluation of the response to treatment; 2) initial staging and disease assessment after orchidectomy identification of suspected recurrences in the context of elevated circulating serum markers; and 3) predicting response to treatment. Of these, the area where FDG-PET imaging has been examined the most in testicular tumors is the evaluation of postchemotherapy residual mass in both seminoma and nonseminomatous germ cell tumors (NSGCT) of the testis, a critical step in determining the subsequent management approach of these tumors that vary amongst various centers. From the available data, this should be the test of choice for the assessment of a computed tomography (CT)-visualized residual mass following chemotherapy. In patients with residual masses or raised marker levels following therapy, positron-emission tomography (PET) appears sensitive and specific for detecting recurrent disease, at suspected and unsuspected sites. Fewer studies are available investigating its usefulness for staging at diagnosis and this requires further investigation to determine its eventual place as an imaging modality in this setting. Its precise role in disease prognostification is yet to be clearly defined in this malignancy but the initial results are promising. With regard to its role in ovarian carcinoma, it appears to be particularly useful for the diagnosis of recurrence when CA125 levels are rising and conventional imaging is inconclusive or negative. The role of fluoro-D-deoxyglucose (FDG)-PET/CT for the detection of recurrent ovarian cancer appears very promising and has the potential to replace the current surveillance techniques in detecting recurrent disease. |
| | |
Authors:
|
S Basu; D Rubello |
Related Documents
:
|
17428168 - Is 18f fdg pet-ct cost effective in lung cancer? 3672658 - Staging of bladder carcinoma by magnetic resonance imaging. a preliminary report. 17411738 - Imaging to optimally stage lung cancer: conventional modalities and pet/ct. 19124108 - Prediction of metastatic disease and survival in patients with gastric and gastroesopha... 12581048 - Mri in ankle tuberculosis: review of 14 cases. 18654288 - Nuclear magnetic resonance imaging with 90-nm resolution. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Minerva endocrinologica Volume: 33 ISSN: 0391-1977 ISO Abbreviation: Minerva Endocrinol. Publication Date: 2008 Sep |
Date Detail:
|
Created Date: 2008-10-10 Completed Date: 2009-01-07 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8406505 Medline TA: Minerva Endocrinol Country: Italy |
Other Details:
|
Languages: eng Pagination: 229-56 Citation Subset: IM |
Affiliation:
|
Radiation Medicine Centre (BARC), Tata Memorial Hospital Annexe, Parel, Bombay, India. drsanb@yahoo.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Antineoplastic Combined Chemotherapy Protocols / therapeutic use Clinical Trials as Topic Combined Modality Therapy Cost-Benefit Analysis Female Follow-Up Studies Forecasting Humans Lymphoma, Non-Hodgkin / radionuclide imaging, therapy Male Middle Aged Neoplasm Staging / methods Neoplasms, Germ Cell and Embryonal / radionuclide imaging, therapy Ovarian Neoplasms / complications, economics, radionuclide imaging*, therapy Paraneoplastic Cerebellar Degeneration / radionuclide imaging Positron-Emission Tomography* / methods Prognosis Prospective Studies Radiopharmaceuticals / diagnostic use Retrospective Studies Testicular Neoplasms / blood, radionuclide imaging*, therapy |
| Chemical | |
Reg. No./Substance:
|
0/Radiopharmaceuticals |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Amiodarone-induced thyrotoxicosis. A review.
Next Document: PET imaging in neuroendocrine tumors: current status and future prospects.